Edition:
India

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

1.19USD
12:26am IST
Change (% chg)

$0.02 (+1.71%)
Prev Close
$1.17
Open
$1.19
Day's High
$1.20
Day's Low
$1.17
Volume
6,437
Avg. Vol
56,873
52-wk High
$5.59
52-wk Low
$0.34

Chart for

About

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $28.92
Shares Outstanding(Mil.): 26.05
Dividend: --
Yield (%): --

Financials

BRIEF-Cerecor announces leadership changes

* Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​

17 Nov 2017

BRIEF-Cerecor acquires TRX Pharmaceuticals

* Cerecor Inc - ‍Under terms of transactions, Cerecor will make an initial payment of $23 million for purchase of TRX​

17 Nov 2017

BRIEF-Cerecor reports Q3 earnings per share of $0.52

* As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million​

06 Nov 2017

BRIEF-Cerecor Inc says Uli Hacksell retires as CEO, president

* Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer

14 Aug 2017

BRIEF-Cerecor Inc Q2 loss per share $0.14

* In August 2017, co sold its world-wide rights of CERC-501 to Janssen in exchange for an initial payment of $25 million​

14 Aug 2017

BRIEF-Cerecor files for resale from time to time of up to 29.2 mln shares

* Files for resale from time to time of up to 29.2 million shares of its common stock - SEC filing

26 May 2017

Earnings vs. Estimates